Trials / Completed
CompletedNCT02879578
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Neurocrine Biosciences · Industry
- Sex
- All
- Age
- 6 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valbenazine |
Timeline
- Start date
- 2016-07-25
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2016-08-25
- Last updated
- 2021-04-29
- Results posted
- 2021-04-29
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02879578. Inclusion in this directory is not an endorsement.